Follow the FIVE PRIME THERAPEUTICS INC share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €12bn. The latest transaction was filed on 8 February 2016 (Cession). Among the most active insiders: Sarena Francis Willard. All data is openly available.
25
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
13 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate FIVE PRIME THERAPEUTICS INC Buy (bullish), based on 21 analysts. Average price target: US$260.48.
Fundamental score
Ranked 15,026 of 29,062 companies
51.1
score / 100
Value
44
Quality
59
FCF yld3.4%
Earn yld3.0%
EV/EBITDA21.6x
ROE21%
Gross mgn36%
Net mgn7.5%
Debt/EBITDA3.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
FIVE PRIME THERAPEUTICS INC es una empresa biofarmacéutica centrada en el desarrollo de terapias innovadoras para el tratamiento del cáncer y otras enfermedades graves. Cotiza en NASDAQ bajo el ticker FPRX.